Description
CAY10583 is a potent and selective full Leukotriene B4 receptor type 2 (BLT2) agonist. CAY10583 directly promotes keratinocyte migration in vitro and accelerates wound closure in vivo. CAY10583 is a promising pharmaceutical agent for diabetic wounds.
Product information
CAS Number: 862891-27-8
Molecular Weight: 387.47
Formula: C25H25NO3
Chemical Name: 4'-[(N-phenylpentanamido)methyl]-[1,1'-biphenyl]-2-carboxylic acid
Smiles: CCCCC(=O)N(CC1C=CC(=CC=1)C1=CC=CC=C1C(O)=O)C1C=CC=CC=1
InChiKey: IUJTVDNJFPZYBL-UHFFFAOYSA-N
InChi: InChI=1S/C25H25NO3/c1-2-3-13-24(27)26(21-9-5-4-6-10-21)18-19-14-16-20(17-15-19)22-11-7-8-12-23(22)25(28)29/h4-12,14-17H,2-3,13,18H2,1H3,(H,28,29)
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
CAY10583 (1 nM-1μM; 24 hours) promotes wound closure via keratinocyte migration. And CAY10583 has no significant effect of on keratinocyte proliferation.
In Vivo:
CAY10583 (administered topically to full-thickness wounds; 10 μM; 14 days) significantly results in a greater wound closure than the control group. The difference in wound closure between the CAY-treated group and the control group is pronounced over time until day 10. And the difference is approximately 6% at day 4 and reaches almost 20% at day 8. Notably, 100% closure was observed in the CAY-treated group at day 14.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.